CriticalVitamin K antagonist anticoagulants×Antidepressants. Other antidepressants of herbal origin
Updated · Methodology
Mechanism
St John's wort (Hypericum) preparations induce CYP3A4, CYP2B6, CYP2C9, CYP2C19 and P-glycoprotein, and hyperforin does this dose-dependently. Other drugs may then be eliminated faster, and their plasma levels fall (St John's wort monograph, European Medicines Agency, EMA). Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and inducers of CYP2C9, CYP2C19 and CYP3A4 can reduce its anticoagulant effect (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish SmPC of a St John's wort product names acenocoumarol together with warfarin. For both, plasma levels fall, the anticoagulant effect weakens and there is a risk of treatment failure. The anticoagulant dose has to be increased (St John's wort SmPC, AEMPS). The SmPC of a generic acenocoumarol adds that the interaction has been described with warfarin and phenprocoumon and cannot be excluded for acenocoumarol (generic acenocoumarol SmPC, AEMPS).
Symptoms
Acenocoumarol plasma levels fall, its anticoagulant effect weakens, and there is a risk of treatment failure (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens. After St John's wort is stopped, the raised enzyme activity returns to normal within a week (St John's wort monograph, European Medicines Agency, EMA). The effect of acenocoumarol can then increase again, especially if its dose was raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).
Management
The combination is contraindicated. The St John's wort monograph of the European Medicines Agency (EMA) contraindicates St John's wort with coumarin-type anticoagulants, which include acenocoumarol. For well-established use products it applies without conditions, and for traditional use products it applies when the daily hyperforin dose exceeds 1 mg (St John's wort monograph, EMA, sections 4.3 and 4.5). The Spanish summary of product characteristics (SmPC) of a St John's wort product also contraindicates coumarin-type anticoagulants. Its interaction table lists acenocoumarol with warfarin among the drugs that must not be taken with St John's wort (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of that product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. For traditional use products with a daily hyperforin intake of up to 1 mg, taken for no longer than 2 weeks, the monograph reports no clinically relevant interactions. This applies to drugs metabolised via CYP1A2, CYP2B6, CYP2C9, CYP2C19 or CYP3A4 or transported by P-glycoprotein (St John's wort monograph, EMA, section 4.5). The acenocoumarol SmPCs are less strict. They list St John's wort among drugs that need close and frequent coagulation checks, for example twice a week, both when they are added and when they are stopped (acenocoumarol SmPCs, AEMPS). If St John's wort has already been taken with acenocoumarol, check coagulation just as often after it is stopped (acenocoumarol SmPCs, AEMPS). The raised enzyme activity returns to normal within a week (St John's wort monograph, EMA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5
- AEMPS: Ficha técnica: Hipérico (nº registro 79963), sección 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras (Arkopharma), nº registro 79963, revisión 11/2025 (texto de septiembre de 2016), secciones 4.3, 4.5 y 5.2; autorización suspendida desde el 11/06/2026, no hay otra ficha técnica de hipérico vigente en CIMA
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.2